Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 5
2022 1
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety.
Luxi N, Giovanazzi A, Capuano A, Crisafulli S, Cutroneo PM, Fantini MP, Ferrajolo C, Moretti U, Poluzzi E, Raschi E, Ravaldi C, Reno C, Tuccori M, Vannacci A, Zanoni G, Trifirò G; Ilmiovaccino COVID19 collaborating group. Luxi N, et al. Drug Saf. 2021 Dec;44(12):1247-1269. doi: 10.1007/s40264-021-01131-6. Epub 2021 Nov 5. Drug Saf. 2021. PMID: 34739716 Free PMC article. Review.
Anaphylaxis due to antiallergic and antiasthmatic biologics.
Furci F, Luxi N, Senna G, Trifirò G. Furci F, et al. Among authors: luxi n. Curr Opin Allergy Clin Immunol. 2023 Oct 1;23(5):364-369. doi: 10.1097/ACI.0000000000000937. Epub 2023 Jul 25. Curr Opin Allergy Clin Immunol. 2023. PMID: 37555938 Review.
Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials.
Ahmadizar F, Luxi N, Raethke M, Schmikli S, Riefolo F, Saraswati PW, Bucsa C, Osman A, Liddiard M, Maques FB, Petrelli G, Sonderlichová S, Thurin NH, Villalobos F, Trifirò G, Sturkenboom M; ilmiovaccinoCOVID19 collaborating group. Ahmadizar F, et al. Among authors: luxi n. Drug Saf. 2023 Jun;46(6):575-585. doi: 10.1007/s40264-023-01304-5. Epub 2023 Apr 27. Drug Saf. 2023. PMID: 37103643 Free PMC article.
Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy.
Ciccimarra F, Luxi N, Bellitto C, L' Abbate L, De Nardo P, Savoldi A, Yeomans A, Molokhia M, Tacconelli E, Trifirò G. Ciccimarra F, et al. Among authors: luxi n. BioDrugs. 2023 Sep;37(5):675-684. doi: 10.1007/s40259-023-00601-w. Epub 2023 May 6. BioDrugs. 2023. PMID: 37148526 Free PMC article.
Cohort Event Monitoring of Adverse Reactions to COVID-19 Vaccines in Seven European Countries: Pooled Results on First Dose.
Raethke M, van Hunsel F, Thurin NH, Dureau-Pournin C, Mentzer D, Kovačić B, Mirošević Skvrce N, De Clercq E, Sabbe M, Trifirò G, Luxi N, Giovanazzi A, Shakir S, Klungel OH, Schmikli S, Sturkenboom M. Raethke M, et al. Among authors: luxi n. Drug Saf. 2023 Apr;46(4):391-404. doi: 10.1007/s40264-023-01281-9. Epub 2023 Apr 7. Drug Saf. 2023. PMID: 37024736 Free PMC article.
Suspected adverse reactions to medications and food supplements containing Serenoa repens: A worldwide analysis of pharmacovigilance and phytovigilance spontaneous reports.
Crescioli G, Maggini V, Raschi E, Gonella LA, Luxi N, Ippoliti I, Di Giovanni V, Bonaiuti R, Firenzuoli N, Gallo E, Menniti-Ippolito F, Moretti U, Trifirò G, Vannacci A, Firenzuoli F, Lombardi N. Crescioli G, et al. Among authors: luxi n. Phytother Res. 2023 Nov;37(11):5289-5299. doi: 10.1002/ptr.7960. Epub 2023 Jul 18. Phytother Res. 2023. PMID: 37463655
16 results